Prelude Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Prelude Capital Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11,900	Closed	-$571K	–	2398
2020 Q1	$571K	Sell	11,900 -19,359	-62%	-$901K	0.04%	303
2019 Q4	$1.47M	Buy	+31,259	New	+$1.38M	0.06%	276
2018 Q4	–	Sell	-19,246	Closed	-$348K	–	2334
2018 Q3	$348K	Buy	+19,246	New	+$228K	0.02%	631

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Prelude Capital Management's RARX Position: Q2 2020 in Review

Prelude Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 11,900 shares — an estimated $571K sold.

Prelude Capital Management first reported a position in RARX in Q3 2018 and held it in 3 quarters. The position peaked at $1.47M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Prelude Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Prelude Capital Management sold 11,900 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $571K.
Prelude Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
Prelude Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $1.47M in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Prelude Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.